Utilization of a CMV T Cell Immunity Assay to Guide Secondary Prophylaxis in Solid Organ Transplant Recipients
Transplant Infectious Disease · 2026
DOI: 10.1111/tid.70185 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, 2026. Verfasst von Christina Doligalski und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, UNC Health, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, T-Lymphocytes, Cytomegalovirus, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Secondary prophylaxis following treatment of CMV infection in solid organ transplant recipients (SOTRs) may be considered in high‐risk SOTRs, although utilization criteria are not well described. The addition of CMV‐specific T‐cell immunity assay testing may help guide selection of SOTRs for secondary prophylaxis.
Methods
All SOTRs at a single center with CMV T‐cell assays obtained during secondary prophylaxis between January 2020 and August 2023 were reviewed. CMV antiviral secondary prophylaxis discontinuation rates and subsequent need for antiviral therapy re‐initiation were recorded. Positive predictive and negative predictive values of the assay, as well as the association between absolute lymphocyte count (ALC) and CMV T cell assay variables, were assessed.
Results
CMV T‐cell assay results in 32/78 (41%) SOTRs showed adequate response. Secondary prophylaxis was discontinued in 27 (84.4%) with adequate and 13 (28.2%) with inadequate T‐cell response ( p < 0.005). CMV DNAemia requiring re‐initiation of CMV therapy occurred in 2/27 (7.4%) of the adequate and 3/13 (23.1%) of the inadequate response cohorts ( p = 0.056), demonstrating a PPV and NPV of 92.6% and 23.1%, respectively, with 71.4% sensitivity and 60% specificity. When combined with ALC > 0.5 10 9 /L at time of assay, an adequate T cell assay response was significantly associated with no CMV reactivation ( n = 0/22, p < 0.001).
Conclusion
In this exploratory population, the combination of an adequate CMV T‐cell assay with adequate ALC was strongly predictive of no CMV reactivation. Further investigation into the predictive characteristics of a CMV T‐cell assay combined with ALC and other patient‐specific factors may optimize its clinical application. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, UNC Health, Chapel Hill, North Carolina, USA.
- Department of Medicine, UNC Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
ORCID-Profile: Christina Doligalski, Luther Bartelt, Anne M Lachiewicz, Arlene C Seña, Mary Chandran
Zitieren
APA
Doligalski, C., Bartelt, L., Lachiewicz, A. M., Seña, A. C., & Chandran, M. (2026). Utilization of a CMV T Cell Immunity Assay to Guide Secondary Prophylaxis in Solid Organ Transplant Recipients. Transplant Infectious Disease. https://doi.org/10.1111/tid.70185
Vancouver
Doligalski C, Bartelt L, Lachiewicz AM, Seña AC, Chandran M. Utilization of a CMV T Cell Immunity Assay to Guide Secondary Prophylaxis in Solid Organ Transplant Recipients. Transplant Infectious Disease. 2026. doi:10.1111/tid.70185
BibTeX
@article{Doligalski2026,
author = {Doligalski, Christina and Bartelt, Luther and Lachiewicz, Anne M and Seña, Arlene C and Chandran, Mary},
title = {Utilization of a CMV T Cell Immunity Assay to Guide Secondary Prophylaxis in Solid Organ Transplant Recipients},
journal = {Transplant Infectious Disease},
year = {2026},
doi = {10.1111/tid.70185}
}
EUVIMED